Method for preparing VT cell-derived exosomes for treating EPSTEIN-BARR virus-associated cancers
Through Vδ2-T cell-derived exosomes (Vδ2-T-Exos), directly killing and inhibiting EBV-induced B-cell lymphoma, solving the problems of limited treatment options and immunotherapy limitations in the prior art, and achieving EBV induction Effective control and prolonged survival of lymphoma.
Patent Information
- Application Number
- CN202080072732.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-17
- Filing Date
- 2020-08-31
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-08-31
AI Technical Summary
The prior art has limited options for EBV-induced B-cell lymphoma treatment and is not completely effective for recurrent or refractory diseases, and immunotherapy based on Vδ2-T cells has limitations on cell depletion and immunosuppressive microenvironment.
By using Vδ2-T cell-derived exosomes (Vδ2-T-Exos), these exosomes not only directly kill EBV-infected cells, but also indirectly inhibit the development and progression of lymphoma by enhancing T-cell-mediated antitumor activity , new treatments are provided.
Vδ2-T-Exos can effectively target and kill EBV-induced B-cell lymphoma, inhibit tumor development and progression, significantly prolong the survival of mice, and show superiority to autologous Vδ2-T in humanized mice. -The therapeutic effect of Exos.
Smart Images

Figure HDA0003598622010000011 
Figure HDA0003598622010000021 
Figure HDA0003598622010000031
Abstract
Description
Background of the Invention
[0002] Epstein-Barr virus (EBV) persistently infects most adults in an asymptomatic manner; however, it is also associated with a variety of lymphomas. In immunocompromised patients, EBV may cause life-threatening EBV-induced B-cell lymphoproliferative disease (EBV-LPD) and diffuse large B-cell lymphoma. Current treatment options for EBV-associated tumors are very limited, have significant off-target toxicity, and are not completely effective for relapsed or refractory disease. Restoring immunity to EBV by adoptive transfer of in vitro generated EBV-specific cytotoxic T cells (CTLs) has successfully treated EBV-associated tumors in some hematopoietic cell transplant patients. However, this approach is ineffective for EBV-associated tumors in solid organ transplant patients and is also limited by the difficulty of generating sufficient numbers of EBV-specific CTLs in vitro.
[0003] γδ-T cells, as innate T cell-like cells with MHC-independent lytic activity against different tumor cells, have great potential in cancer immunotherapy. Human γδ-T cells are divided into two major subpopulations according to the introduction of Vδ1 or Vδ2 chains into their T cell receptors (TCRs). + T cells predominate in mucosal and epithelial tissues, and most Vδ2 + T cells are present in peripheral blood and lymphoid organs and often co-express Vγ9. Vδ2 + T cells can be activated and expanded in an MHC-independent manner by phosphoantigens, which are small non-peptide phosphorylated intermediates of the mevalonate pathway in mammalian cells. Pamidronate (PAM) is a pharmacological aminobisphosphonate commonly used to treat osteoporosis, which can also selectively activate and expand human Vδ2 in vitro and in vivo. + Recently, using immunodeficient Rag2 - / - γc - / - The humanized mouse EBV-LPD model showed that adoptive transfer of ex vivo PAM-expanded Vδ2 + T cells or direct administration of PAM expands Vδ2 in vivo + T cells can control EBV-LPD, suggesting that Vδ2-T cell-based immunotherapy could be used to treat EBV-induced B-cell cancers. However, its clinical application is limited because Vδ2-T cells in some cancer patients are difficult to expand by phosphoantigens and repeated administration of phosphoantigens may lead to Vδ2-T cell exhaustion. In addition, the antitumor efficacy of cell-based immunotherapy may be severely hampered by the immunosuppressive tumor microenvironment in patients. SUMMARY OF THE INVENTION
[0005] The present disclosure provides human Vδ2-T cell-derived exosomes (Vδ2-T-Exos) that not only directly kill EBV-induced B-cell lymphomas, but also indirectly inhibit the development and progression of lymphomas by enhancing T cell-mediated anti-tumor activity. Therefore, certain embodiments of the present invention provide methods for killing EBV-infected cells or inhibiting their growth by contacting cells with Vδ2-T-Exos. Further embodiments of the present invention also provide methods for treating EBV-induced cancers such as EBV-induced B-cell lymphomas by administering Vδ2-T-Exos to subjects. Even further embodiments of the present invention provide methods for isolating Vδ2-T-Exos. BRIEF DESCRIPTION OF THE DRAWINGS
[0006] Figure 1A. Characterization of Vδ2-T-Exos. Size distribution of Vδ2-T-Exos measured by dynamic light scattering analysis.
[0007] Figure 1B. Characterization of Vδ2-T-Exos. The morphology of Vδ2-T-Exos was determined by transmission electron microscopy. Scale bar, 50 nm.
[0008] Figure 1C. Characterization of Vδ2-T-Exos. Exosomal markers CD63, TSG101, CD81, Alix and endoplasmic reticulum marker GRP94 were measured in Vδ2-T cells and Vδ2-T-Exos by Western blot analysis.
[0009] Figure 1D. Characterization of Vδ2-T-Exos. Surface expression of functional molecules on Vδ2-T-Exos was determined by flow cytometry, and the gray histogram represents the isotype control. Each experiment was performed four times independently.
[0010] Figure 1E. Characterization of Vδ2-T-Exos. Surface expression of functional molecules on Vδ2-T-Exos was determined by flow cytometry, and the gray histogram represents the isotype control. Each experiment was performed four times independently.
[0011] Figure 1F Characterization of Vδ2-T-Exos. Surface expression of functional molecules on Vδ2-T-Exos was determined by flow cytometry, and the gray histogram represents the isotype control. Each experiment was performed four times independently.
[0012] Figure 2A. Vδ2-T-Exos target EBV-induced B-cell lymphoma. Vδ2-T-Exos were labeled with Dil and then co-cultured with EBV-LCL. After 18 hours, Dil signals in EBV-LCL were analyzed by confocal microscopy. DAPI was used to stain the nucleus (Dil = red, DAPI = blue; scale bar = 10 μm). *p < 0.05, **p < 0.01. NS, not significant.
[0013] Figure 2B. Vδ2-T-Exos target EBV-induced B-cell lymphoma. DiR-labeled Vδ2-T-Exos were intraperitoneally injected into mice bearing EBV-induced B-cell lymphoma. Tumor tissues were harvested 3 hours or 24 hours later. The fluorescence intensity of DiR-labeled Vδ2-T-Exos was measured using an in vivo imaging system. *p<0.05, **p<0.01. NS, not significant.
[0014] Figure 2C. Vδ2-T-Exos target EBV-induced B-cell lymphoma. CFSE-labeled Vδ2-T-Exos were co-cultured with EBV-LCL and autologous normal B cells for 18 hours. CFSE signals in cells were detected by flow cytometry. *p<0.05, **p<0.01. NS, not significant.
[0015] Figure 2D. Vδ2-T-Exos target EBV-induced B-cell lymphoma. CFSE-labeled Vδ2-T-liposomes were co-cultured with EBV-LCL and autologous normal B cells for 18 hours. CFSE signals in cells were detected by flow cytometry. *p<0.05, **p<0.01. NS, not significant.
[0016] Figure 2E. Vδ2-T-Exos target EBV-induced B-cell lymphoma. CFSE-labeled Vδ2-T-Exos were pre-incubated with neutralizing anti-NKG2D antibody or isotype control and then co-cultured with EBV-LCL. CFSE signal on EBV-LCL was measured after 18 hours. The pellet isolated from non-conditioned Exos-free medium without Vδ2-T cell components was used as a control. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01. NS, not significant.
[0017] Figure 2F .Vδ2-T-Exos target EBV-induced B-cell lymphoma. CFSE-labeled Vδ2-T-Exos were pre-incubated with neutralizing anti-TCR-γδ antibody or isotype control and then co-cultured with EBV-LCL. CFSE signal on EBV-LCL was measured after 18 hours. Precipitate isolated from non-conditioned Exos-free medium without Vδ2-T cell components was used as control. All data shown as mean ± SEM are representative of four independent experiments. *p < 0.05, **p < 0.01. NS, not significant.
[0018] Figure 3A. Vδ2-T-Exos induce apoptosis of EBV-LCL. Apoptosis of EBV-LCL and autologous normal B cells was measured after co-culture with different amounts of Vδ2-T-Exos for 18 hours. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01. NS, not significant.
[0019] Figure 3B. Vδ2-T-Exos induce apoptosis of EBV-LCL. Active caspase-3 was measured in EBV-LCL after 4 h of co-culture with Vδ2-T-Exos or PBS. All data shown as mean ± SEM are representative of four independent experiments. *p<0.05, **p<0.01. NS, not significant.
[0020] Figure 3C. Vδ2-T-Exos induce apoptosis of EBV-LCL. Surface expression of Fas and DR5 on EBV-LCL and autologous normal B cells was determined by flow cytometry. Representative images are shown, and gray histograms represent isotype controls. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01. NS, not significant.
[0021] Figure 3D .Vδ2-T-Exos induce apoptosis of EBV-LCL. Vδ2-T-Exos pretreated with or without neutralizing anti-FasL, anti-TRAIL antibodies or corresponding isotype controls were co-cultured with EBV-LCL. Apoptosis was calculated as the percentage inhibition relative to Vδ2-T-Exos without pretreatment. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01. NS, not significant.
[0022] Figure 4A. Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. - / - γc - / - The EBV-induced B cell lymphoma model was established by subcutaneous injection of EBV-LCL expressing EGFP in mice. Vδ2-T-Exos were intraperitoneally injected into Rag2 - / - γc - / - Mice. An equal volume of PBS was used as a control. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0023] Figure 4B. Vδ2-T-Exos control Rag2 - / - γc - / -EBV-induced B-cell lymphoma in mice. Whole-body fluorescent images of mice were measured using an in vivo imaging system 30 days after subcutaneous inoculation with EBV-LCL (n=6) or PBS (n=6). Data are expressed as mean ± SEM. *p<0.05, **p<0.01. NS, not significant.
[0024] Figure 4C .Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. Tumor incidence was measured at the indicated times after treatment with Vδ2-T-Exos or PBS. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0025] Figure 4D. Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. Representative histology, in situ hybridization for EBER-1 / 2, and histochemical analysis of human Ki-67 of tumor sections from mice receiving Vδ2-T-Exos or PBS (scale bar = 100 μm). Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0026] Figure 4E. Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. Tumor volume was measured at the end point. Data are presented as mean ± SEM. *p<0.05, **p<0.01. NS, not significant.
[0027] Figure 4F. Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. Mouse survival was determined at the indicated times (6 mice per group). Data are presented as mean ± SEM. *p<0.05, **p<0.01. NS, not significant.
[0028] Figure 4G .Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. EBV-LCL expressing EGFP were injected subcutaneously into Rag2 - / - γc - / -Mice. Fourteen days later, mice that had developed subcutaneous tumors as determined by the in vivo imaging system were randomly divided into two groups and then treated with Vδ2-T-Exos or PBS at the indicated time (8 mice per group). Data are expressed as mean ± SEM. *p<0.05, **p<0.01. NS, not significant.
[0029] Figure 4H. Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. Whole-body fluorescent images of mice before treatment with Vδ2-T-Exos or PBS. Data are presented as mean ± SE M. *p<0.05, **p<0.01. NS, not significant.
[0030] Figure 4I. Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. Mouse survival was determined at the indicated times. Data are presented as mean ± SEM. *p<0.05, **p<0.01. NS, not significant.
[0031] Figure 4J. Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. Tumor volumes were determined at indicated times. Data are presented as mean ± SEM. *p<0.05, **p<0.01. NS, not significant.
[0032] Figure 4K .Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice. Representative histology, in situ hybridization for EBER-1 / 2, and histochemical analysis of human Ki-67 of tumor sections from mice receiving Vδ2-T-Exos or PBS (scale bar = 100 μm). Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0033] Figure 5A. Vδ2-T-Exos control EBV-induced B cell lymphoma in humanized mice. An EBV-induced B cell lymphoma model was established by subcutaneous injection of autologous EBV-LCL expressing EGFP in humanized mice. Vδ2-T-Exos allogeneic with reconstructed huPBMC were intraperitoneally injected into humanized mice at the specified time. An equal volume of PBS was used as a control (8 mice per group). Data are expressed as mean ± SEM. *p<0.05, **p<0.01. NS, not significant.
[0034] Figure 5B. Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. Tumor incidence was determined at endpoint or indicated time. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0035] Figure 5C. Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. Tumor volume was measured at the endpoint or indicated time. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0036] Figure 5D. Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. Mouse survival was measured at the endpoint or indicated time. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0037] Figure 5E .Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. Representative histology, in situ hybridization for EBER-1 / 2, and histochemical analysis of human Ki-67 of tumor sections from mice receiving Vδ2-T-Exos or PBS (scale bar = 100 μm). Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0038] Figure 5F. Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. EBV-LCL were injected subcutaneously in the Rag2 - / - γc - / - EBV-induced B-cell lymphoma models were established in mice and humanized mice, and Rag2 - / - γc - / - or humanized mice were treated with autologous or allogeneic Vδ2-T-Exos. An equal volume of PBS was used as a control (8 mice per group). Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0039] Fig. 5G. Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. Tumor incidence was measured at endpoint or indicated time. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0040] Fig. 5H. Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. Tumor volume was measured at the endpoint or indicated time. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0041] Figure 5I. Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. Mouse survival was measured at the endpoint or indicated time. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0042] Figure 5J. Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. Representative histology, in situ hybridization of EBER-1 / 2, and histochemical analysis of human Ki-67 from tumor sections of humanized mice receiving autologous Vδ2-T-Exos, allogeneic Vδ2-T-Exos, or PBS (scale bar = 100 μm). Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0043] Figure 5K .Vδ2-T-Exos control EBV-induced B-cell lymphoma in humanized mice. Representative immunofluorescence analysis of human CD3 T cells in tumor sections from humanized mice receiving autologous Vδ2-T-Exos, allogeneic Vδ2-T-Exos, or PBS (CD3 = red, DAPI = blue; scale bar = 20 μm). Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01. NS, not significant.
[0044] Figure 6A. Vδ2-T-Exos induce CD4 T cell and CD8 T cell-mediated anti-tumor responses. Vδ2-T-Exos were labeled with CFSE and then co-cultured with CD3 T cells. After 18 hours, CFSE signals on CD4 or CD8 T cells were determined by flow cytometry. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0045] Figure 6B. Vδ2-T-Exos induce CD4 T cell and CD8 T cell-mediated anti-tumor responses. Vδ2-T-Exos were labeled with CFSE and then co-cultured with CD3 T cells. After 18 hours, CFSE signals on CD4 or CD8 T cells were determined by flow cytometry. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0046] Figure 6CVδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated antitumor responses. Expression of CCR5 on CD4 T cells and CD8 T cells after co-culture of CD3 T cells with allogeneic Vδ2-T-Exos or PBS for 48 h. All data shown as mean ± SEM are representative of four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0047] Fig. 6D. Vδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated antitumor responses. Expression of CCR5 on CD4 T cells and CD8 T cells after co-culture of CD3 T cells with allogeneic Vδ2-T-Exos or PBS for 48 h. All data shown as mean ± SEM are representative of four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
[0048] Figure 6E. Vδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated anti-tumor responses. CD3 T cells pretreated with Vδ2-T-Exos were incubated with neutralizing anti-CCR5 antibodies or isotype controls for 30 minutes and added to the upper chamber. PBS-pretreated CD3 T cells were used as controls. Supernatants from EBV-LCL were added to the lower chamber. The relative percentage of cells that migrated from the upper chamber after 4 hours is shown. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0049] Fig. 6F. Vδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated antitumor responses. Proliferation of CD4 or CD8 T cells and intracellular expression of IFN-γ after culturing CD3 T cells with different amounts of autologous or allogeneic Vδ2-T-Exos for 7 days. Representative images of flow cytometry are shown on the left. All data shown as mean ± SEM are representative of four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0050] Fig. 6G. Vδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated antitumor responses. Proliferation of CD4 or CD8 T cells and intracellular expression of IFN-γ after culturing CD3 T cells with different amounts of autologous or allogeneic Vδ2-T-Exos for 7 days. Representative images of flow cytometry are shown on the left. All data shown as mean ± SEM are representative of four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0051] Figure 6H.Vδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated antitumor responses. Proliferation of CD4 or CD8 T cells and intracellular expression of IFN-γ after culturing CD3 T cells with different amounts of autologous or allogeneic Vδ2-T-Exos for 7 days. Representative images of flow cytometry are shown on the left. All data shown as mean ± SEM are representative of four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0052] Fig. 6I. Vδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated antitumor responses. Proliferation of CD4 or CD8 T cells and intracellular expression of IFN-γ after culturing CD3 T cells with different amounts of autologous or allogeneic Vδ2-T-Exos for 7 days. Representative images of flow cytometry are shown on the left. All data shown as mean ± SEM are representative of four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0053] Fig. 6J. Vδ2-T-Exos induce CD4 T cells and CD8 T cells mediated anti-tumor response. EBV-specific cytotoxic T lymphocytes (EBV-CTLs) were selected from EBV serum-positive huPBMCs and co-cultured with allogeneic Vδ2-T-Exos or PBS in the presence of IL-2. Two weeks later, the cell number of EBV-CTLs was determined by intracellular staining of IFN-γ and counted by counting beads. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01, ***p<0.001. EBV-specific cytotoxic T lymphocytes (EBV-CTLs) were selected from EBV serum-positive huPBMCs and co-cultured with allogeneic Vδ2-T-Exos or PBS in the presence of IL-2. Two weeks later, the cell number of EBV-CTLs was determined by intracellular staining of IFN-γ and counted by counting beads. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0054] Figure 6K.Vδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated anti-tumor responses. EBV-specific cytotoxic T lymphocytes (EBV-CTLs) were selected from EBV seropositive huPBMCs and co-cultured with allogeneic Vδ2-T-Exos or PBS in the presence of IL-2. Two weeks later, the cell number of EBV-CTLs was determined by intracellular staining of IFN-γ and counted by counting beads. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01, ***p<0.001. EBV-specific cytotoxic T lymphocytes (EBV-CTLs) were selected from EBV seropositive huPBMCs and co-cultured with allogeneic Vδ2-T-Exos or PBS in the presence of IL-2. Two weeks later, the cell number of EBV-CTLs was determined by intracellular staining of IFN-γ and counted by counting beads. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01, ***p<0.001.
[0055] Figure 7A. CD4 T cells and CD8 T cells participate in Vδ2-T-Exos-induced anti-tumor immunity in humanized mice. The EBV-induced B cell lymphoma model was established by injecting autologous EBV-LCL in humanized mice reconstructed with full huPBMC, CD4-T cell-depleted huPBMC or CD8-T cell-depleted huPBMC from the same donor. Allogeneic Vδ2-T-Exos were intraperitoneally injected into humanized mice (8 mice per group) at the specified time. Data are expressed as mean ± SEM. *p<0.05, NS, not significant.
[0056] Figure 7B. CD4 T cells and CD8 T cells are involved in Vδ2-T-Exos-induced anti-tumor immunity in humanized mice. Tumor incidence was measured at the endpoint or at the indicated time. Data are expressed as mean ± SEM. *p < 0.05, NS, not significant.
[0057] Figure 7C. CD4 T cells and CD8 T cells are involved in Vδ2-T-Exos-induced anti-tumor immunity in humanized mice. Tumor volume was measured at the endpoint or at the indicated time. Data are expressed as mean ± SEM. *p < 0.05, NS, not significant.
[0058] Fig.7D CD4 T cells and CD8 T cells are involved in Vδ2-T-Exos-induced antitumor immunity in humanized mice. Mouse survival was measured at the endpoint or at the indicated time. Data are expressed as mean ± SEM. *p < 0.05, NS, not significant.
[0059] Figure 8A. Characterization of Vδ2-T-Exos. Extracellular vesicles derived from Vδ2-T cells were separated into 12 subfractions by iodixanol gradient. Representative data are shown as mean ± SEM of four independent experiments. **p < 0.01.
[0060] Figure 8B. Characterization of Vδ2-T-Exos. Western blot analysis of exosome markers CD81, TSG101, CD63 and Alix in subfractions after iodixanol gradient separation. Representative data are shown as mean ± SEM of four independent experiments. **p < 0.01.
[0061] Figure 8C Characterization of Vδ2-T-Exos. Apoptosis of EBV-LCL after 18 h of culture of gradient subfractions. Representative data are shown as mean ± SEM of four independent experiments. **p < 0.01.
[0062] Fig. 9 Activation and functional markers of Vδ2-T cells. The indicated cell surface markers were determined by flow cytometry on resting Vδ2-T cells (day 0) or PAM-expanded Vδ2-T cells (day 16). Gray histograms represent isotype controls. Data are shown as representatives of four independent experiments.
[0063] Figure 10A. Role of HLA and CD86 in T cell responses induced by Vδ2-T-Exos. Proliferation of CD4 T cells after culturing CD3 T cells with allogeneic Vδ2-T-Exos, neutralizing anti-HLA-DR / DP / DQ antibodies or isotype control pre-treated Vδ2-T-Exos. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01. NS, not significant.
[0064] Figure 10B. Role of HLA and CD86 in T cell responses induced by Vδ2-T-Exos. Intracellular expression of IFN-γ in CD4 T cells after culturing CD3 T cells with allogeneic Vδ2-T-Exos, neutralizing anti-HLA-DR / DP / DQ antibodies or isotype control pretreated Vδ2-T-Exos. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01. NS, not significant.
[0065] Figure 10C. Role of HLA and CD86 in T cell responses induced by Vδ2-T-Exos. Proliferation of CD8 T cells after culturing CD3 T cells with allogeneic Vδ2-T-Exos, neutralizing anti-HLA-A / B / C antibodies or isotype control pretreated Vδ2-T-Exos. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01. NS, not significant.
[0066] Fig. 10D Role of HLA and CD86 in T cell responses induced by Vδ2-T-Exos. Intracellular expression of IFN-γ in CD8 T cells after culture of CD3 T cells with allogeneic Vδ2-T-Exos, neutralizing anti-HLA-A / B / C antibodies, or isotype control pretreated Vδ2-T-Exos. All data shown as mean ± SEM are representative of four independent experiments. *p < 0.05, **p < 0.01. NS, not significant.
[0067] Figure 10E. Role of HLA and CD86 in T cell responses induced by Vδ2-T-Exos. Proliferation of CD4 T cells after culturing CD3 T cells with Vδ2-T-Exos pretreated with allogeneic Vδ2-T-Exos, neutralizing anti-CD86 antibodies, or isotype control. All data shown as mean ± SEM represent four independent experiments. *p < 0.05, **p < 0.01. NS, not significant.
[0068] Figure 10F. Role of HLA and CD86 in T cell responses induced by Vδ2-T-Exos. Intracellular expression of IFN-γ in CD4 T cells after culturing CD3 T cells with Vδ2-T-Exos pretreated with allogeneic Vδ2-T-Exos, neutralizing anti-CD86 antibody, or isotype control. All data shown as mean ± SEM represent four independent experiments. *p<0.05, **p<0.01. NS, not significant.
[0069] Figure 10G. Role of HLA and CD86 in T cell responses induced by Vδ2-T-Exos. Proliferation of CD8 T cells after culture of CD3 T cells with Vδ2-T-Exos pretreated with allogeneic Vδ2-T-Exos, neutralizing anti-CD86 antibody or isotype control. All data shown as mean ± SEM are representative of four independent experiments. *p < 0.05, **p < 0.01. NS, not significant.
[0070] Fig. 10HRole of HLA and CD86 in T cell responses induced by Vδ2-T-Exos. Intracellular expression of IFN-γ in CD8 T cells after culture of CD3 T cells with Vδ2-T-Exos pretreated with allogeneic Vδ2-T-Exos, neutralizing anti-CD86 antibody, or isotype control. All data shown as mean ± SEM are representative of four independent experiments. *p < 0.05, **p < 0.01. NS, not significant.
[0071] Fig.11 .Surface expression of MICA / B on EBV-LCL and autologous normal B cells. Expression of MICA / B on EBV-LCL and autologous normal B cells was determined by flow cytometry, and the gray histogram represents the isotype control. Data represent four independent experiments.
[0072] 12A-12E . Vδ2-T-Exos isolated according to the method disclosed in Example 8. DETAILED DESCRIPTION OF THE INVENTION
[0074] As used herein, the singular forms "a", "an", and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent the terms "includes", "comprising", "including", "having", "having" or variations thereof are used in the detailed description and / or the claims, these terms are intended to be inclusive in a manner similar to the term "comprising". The transitional terms / phrases (and any grammatical variations thereof) "comprising", "including", "containing", "consisting essentially of", "consisting essentially of", "consisting of", and "consisting of" may be used interchangeably.
[0075] The phrase "consisting essentially of" or "consisting essentially of" means that a claim covers embodiments including the specified materials or steps as well as embodiments that do not materially affect the basic and novel characteristics of the claim.
[0076] The term "about" means within an acceptable error range for a particular value determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. Generally, "about" can mean a range of up to 0-10% of a given value.
[0077] In the present disclosure, scope is stated in shorthand form to avoid having to list and describe each value in the scope at length. Where appropriate, any suitable value in the scope can be selected as the upper limit, lower limit or terminal point of the scope. For example, the scope of 0.1-1.0 represents the end value of 0.1 and 1.0, and the intermediate value of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and all intermediate values in the scope of 0.1-1.0, such as 0.2-0.5, 0.2-0.8, 0.7-1.0 etc. It is expected that the value in the scope has at least two significant figures, for example, the scope of 5-10 represents all values including the end value between 5.0 and 10.0 and between 5.00 and 10.00.
[0078] As used herein, "treat," "treat," or "treatment" (and grammatical variations of these terms) are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results, including, but not limited to, a therapeutic benefit. A therapeutic benefit is achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying cancer such that an improvement is observed in the patient, notwithstanding that the patient may still be suffering from the underlying cancer.
[0079] The term "effective amount" or "therapeutically effective amount" of exosomes refers to an amount of the exosomes described herein sufficient to achieve the intended application, including but not limited to cancer treatment. The therapeutically effective amount may vary depending on the subject and the disease condition being treated, such as the subject's weight and age, the severity of the cancer, the mode of administration, etc., which can be easily determined by a person of ordinary skill in the art. The term also applies to a dose that will induce a specific response in the target cell, such as killing the target cell or reducing the proliferation of the target cell. The specific dose will also vary depending on the dosing regimen to be followed, whether it is co-administered with other compounds, the time of administration, the tissue to which it is administered, and the physical delivery system that carries the exosomes.
[0080] "Subject" refers to an animal, such as a mammal, e.g., a human. The methods described herein can be used for preclinical human treatment and veterinary applications. In some embodiments, the subject is a mammal (e.g., an animal model of a disease), and in some embodiments, the subject is a human. The terms "subject" and "patient" are used interchangeably.
[0081] Exosomes are small extracellular vesicles (20-200 nm) of endosomal origin that transport lipids, proteins, and nucleic acids in intercellular communication. Exosomes have high bioavailability, biostability, biocompatibility, and cargo loading capacity. Exosomes can be engineered to achieve targeting specificity, making them powerful nanocarriers that can deliver anti-tumor agents and induce antigen-specific anti-tumor immunity.
[0082] Vδ2 + T cells belong to a subset of T lymphocytes. Vδ2+ T cells are present in peripheral blood and lymphoid organs and often co-express Vγ9. Vδ2 + T cells can be activated and expanded in an MHC-independent manner by phosphoantigens, which are small non-peptide phosphorylated intermediates of the mevalonate pathway in mammalian cells. PAM is a pharmacological aminobisphosphonate commonly used to treat osteoporosis, which can also selectively activate and expand human Vδ2 in vitro and in vivo. + T cells.
[0083] Usually, EBV infection is asymptomatic because the infection is controlled by the host's immune system. However, some individuals may suffer from self-limiting infectious mononucleosis, while other individuals may suffer from lymphoma or epithelial cancer associated with EBV. The EBV life cycle includes a lytic phase that causes new viral particles to be produced and a latent phase in which the virus remains essentially silent in memory B cells throughout the host's life. Therefore, the cells infected by EBV can have EBV viruses in the lytic phase or latent phase.
[0084] For the purposes of the present invention, the phrase "from Vδ2 + T cell exosomes refer to exosomes from Vδ2 + These exosomes can be isolated from Vδ2 obtained from a subject to be treated for EBV-induced cancer. + T cells, the EBV-induced cancer is, for example, an EBV-induced B-cell cancer. These exosomes can also be isolated from healthy individuals. Vδ2 can be activated in vitro + T cells are obtained from the subject before or after Vδ2 + T cells isolate exosomes. Typically, Vδ2 + T cells are activated in vitro in the presence of phosphoantigens such as isopentenyl pyrophosphate (IPP), (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate (HMB-PP), bromohydrin pyrophosphate (BrHPP), and PAM. + Other examples of T cell phosphoantigens are known in the art and such embodiments are within the scope of the present invention.
[0085] Certain methods for isolating exosomes are known in the art and can be used to isolate Vδ2 + Exosomes isolated from T cells. Typically, exosomes from cultured Vδ2 + The supernatant of T cells was used as a source of exosomes.
[0086] Immunotherapy based on dendritic cell (DC)-derived exosomes (DC-Exos) or natural killer cell-derived exosomes (NK-Exos) has shown promise for cancer treatment, but the antitumor efficacy of this immunotherapy is limited in some cancer patients. The heterogeneity of ex vivo expanded DCs may partly explain the poor efficacy of DC-Exos-based treatments. Exosomes from immature DCs may have immune tolerance activity. Conventional methods have difficulty in generating highly homogeneous human DCs, and their maturation is usually incomplete and asynchronous. Therefore, tolerogenic DC-Exos are often co-isolated with immunostimulatory DC-Exos and worsen their therapeutic outcomes. In addition, large-scale expansion of DCs or NK cells in vitro remains a challenge. In contrast, an optimized protocol for in vitro expansion of homogeneous human Vδ2-T cells on a clinical scale by using phosphoantigens is known, which allows the generation of large quantities of Vδ2-T-Exos. Most importantly, the cytolytic activity and immunostimulatory properties of Vδ2-T cells against tumor cells can be maintained even after long-term expansion.
[0087] Although certain other exosomes such as DC-Exos or NK-Exos have been tested for their ability to target and kill cancer cells, the anti-tumor activity of Vδ2-T cell-derived exosomes (Vδ2-T-Exos) remains unknown. The present disclosure provides Vδ2-T-Exos that retain the anti-tumor activity of Vδ2-T cells while avoiding the limitations of cell-based cancer immunotherapy. In particular, human Vδ2-T-Exos effectively induced apoptosis of EBV-LCL in vitro and in Rag2 - / - γc - / - Allogeneic Vδ2-T-Exos inhibited the development of EBV-induced B-cell lymphoma in humanized and humanized mice. Allogeneic Vδ2-T-Exos had stronger antitumor activity than autologous Vδ2-T-Exos, probably because it could induce more powerful CD4 T cell- and CD8 T cell-mediated antitumor immunity.
[0088] Similar to exosomes derived from other cells, the surface of Vδ2-T-Exos is decorated with intact functional molecules from its parental cells. Since human Vδ2-T cells have the characteristics of NK and DC, Vδ2-T-Exos may have dual anti-tumor activity. Similar to exosomes derived from NK cells, Vδ2-T-Exos have been found to carry FasL and TRAIL (Figure 1), which can interact with Fas and DR5 expressed on EBV-LCL, respectively (Figure 3), and then induce EBV-LCL apoptosis (Figure 3), thereby effectively inhibiting Rag2 through the Fas / FasL and TRAIL / DR5 pathways. - / - γc - / -(Figure 4) and humanized mice (Figure 5) . Similar to exosomes derived from DCs, Vδ2-T-Exos also retain basic immunostimulatory molecules and MHC-I / II molecules required for antigen presentation and T cell priming, such as CD80, CD86, HLA-A / B / C, and HLA / DR / DP / DQ (Figure 1). In fact, Vδ2-T-Exos can enhance the cell proliferation and IFN-γ production of CD4 cells by recognizing HLA-DR / DP / DQ and CD86 (Figure 6, Figure 10). In addition, both CD4 T cells and CD8 T cells are involved in Vδ2-T-Exos-mediated antitumor immunity against EBV-induced B cell lymphoma in humanized mice (Figure 7). Therefore, Vδ2-T-Exos have multiple antitumor activities and have the antitumor properties of NK-Exos and DCs-Exos.
[0089] The present disclosure demonstrates that Vδ2-T-Exos can target EBV-LCLs through the interaction of NKG2D carried by Vδ2-T-Exos with its ligand MICA / B constitutively expressed on EBV-LCLs ( FIGS. 2E and Fig.11 This targeting effect is independent of the TCR-γδ carried by Vδ2-T-Exos ( Figure 2F ). Since low pH conditions can improve the uptake of exosomes by tumor cells, the acidic conditions in the tumor microenvironment, which is a hallmark of tumor malignancy, may also be responsible for the accumulation of Vδ2-T-Exos at tumor sites.
[0090] Importantly, allogeneic Vδ2-T-Exos can increase T cell infiltration in EBV-induced tumor tissues by upregulating CCR5 on T cells, because EBV-induced lymphoma cells can secrete abundant CCR5 ligands. In addition, allogeneic Vδ2-T-Exos more effectively induced cell proliferation and IFN-γ production of CD4 and CD8 T cells than autologous Vδ2-T-Exos ( Figures 6H-6K ), so allogeneic Vδ2-T-Exos have a superior therapeutic effect than autologous Vδ2-T-Exos on EBV-induced B-cell lymphoma in humanized mice (Figures 5F-5J). In fact, once the HLA-DR / DP / DQ molecules carried on allogeneic Vδ2-T-Exos are blocked, the CD4 T cell response induced by Vδ2-T-Exos can be significantly eliminated (Figure 10), indicating that the allogeneic recognition of HLA-DR / DP / DQ molecules on allogeneic Vδ2-T-Exos plays an important role in inducing T cell responses.
[0091] Therefore, the present disclosure provides a new therapeutic strategy for treating EBV-induced B-cell lymphoma using Vδ2-T-Exos. As a cell-free therapy, Vδ2-T-Exos has the advantages of NK-Exos and DC-Exos by inheriting the cytotoxic and immunostimulatory properties from Vδ2-T cells, enabling it to effectively control EBV-induced B-cell lymphoma. Vδ2-T-Exos-based therapies, especially allogeneic Vδ2-T-Exos-based therapies, have great potential to overcome the shortcomings of conventional immunotherapy for EBV-induced B-cell lymphoma.
[0092] Therefore, certain embodiments of the present invention provide a method for killing or inhibiting the growth of EBV-infected cells, comprising contacting EBV-infected cells with an amount effective to kill or inhibit the growth of the cells derived from Vδ2. + In some embodiments, the EBV-infected cells are EBV-infected lymphocytes, such as B lymphocytes. In other embodiments, the EBV-infected cells are EBV-infected epithelial cells. In a preferred embodiment, the EBV-infected cells have become neoplastic, such as EBV-infected neoplastic B-lymphocytes or EBV-infected neoplastic epithelial cells.
[0093] In certain embodiments, exosomes are isolated from Vδ2 autologous to EBV-infected cells. + Preferably, the exosomes are isolated from Vδ2 cells allogeneic to EBV-infected cells. + T cells.
[0094] A further embodiment of the present invention provides a method of treating EBV-induced cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Vδ2 + T cell exosomes.
[0095] For purposes of the present invention, the phrase "EBV-induced cancer" refers to a cancer arising from EBV-infected cells that have become neoplastic. EBV typically infects lymphocytes or epithelial cells. Thus, the present disclosure provides methods for treating cancers of lymphocyte origin or epithelial origin.
[0096] The lymphocytes that EBV usually infects are B cells. Therefore, the present disclosure provides methods for treating EBV-induced neoplasms (neoplasms), such as EBV-induced B-cell neoplasms, including EBV-induced: Burkitt's lymphoma, Hodgkin's lymphoma, diffuse large B-cell lymphoma and lymphoproliferative diseases.
[0097] The present disclosure also provides methods of treating EBV-induced epithelial cancers, such as EBV-induced nasopharyngeal carcinoma (NPC) or EBV-induced gastric cancer / carcinoma.
[0098] Since most cancer patients are immunocompromised, it is difficult to expand their Vδ2-T cells in vitro on a large scale and prepare autologous Vδ2-T-Exos. In addition, the components of Vδ2-T-Exos from different patients are also different, which may lead to differences in their therapeutic effects. In contrast, it is convenient to expand and prepare allogeneic Vδ2-T-Exos on a large scale from healthy individuals by currently available protocols. Allogeneic Vδ2-T cells can control tumor growth in patients with cholangiocarcinoma without side effects. Since phosphoantigen-expanded Vδ2-T cells show homogeneous antitumor properties, pooling allogeneic Vδ2-T-Exos from a large number of healthy individuals may be beneficial for quality control, standardization, and centralization. Therefore, cancer treatment based on allogeneic rather than autologous Vδ2-T-Exos may be more effective and feasible in future clinical practice.
[0099] Approximately 1-10% of T lymphocytes in an individual can respond to foreign MHC molecules through direct T cell allorecognition. These high-frequency precursors are also specific for antigens presented by self-MHC molecules, and these precursors have been found on multiple occasions against viral peptides and include CD4 T cells and CD8 T cells. In addition, allogeneic responses can promote effective T cell responses to self-HLA-restricted tumor antigens and reverse the exhaustion of pre-existing antigen-specific cytotoxic T lymphocytes, thereby promoting immune clearance of tumor cells. Therefore, this cross-reaction can be proposed for the treatment of viral infections and cancer. The present disclosure also shows that allogeneic Vδ2-T-Exos can promote the expansion of pre-existing EBV-specific CD4 T cells and CD8 T cells, which can be beneficial to the anti-tumor efficacy of Vδ2-T-Exos against EBV-induced B-cell lymphoma.
[0100] Thus, while exosomes can be isolated from Vδ2-T cells of a subject suffering from cancer, in a preferred embodiment, the present invention provides for the isolation of exosomes from Vδ2-T cells of a subject suffering from cancer by administering + The invention relates to a method for treating EBV-induced cancer in a subject, preferably a healthy individual allogeneic to the subject, by using exosomes obtained from T cells.
[0101] Alternatively, when the subject is known to be cancer-free, Vδ2 + Therefore, exosomes can be obtained from Vδ2 T cells from subjects. +The exosomes are acquired by the T cells and stored under appropriate conditions, such as frozen, and administered to the subject if the subject develops an EBV-induced cancer.
[0102] Exosomes can be administered to a subject by any convenient and effective route of administration, such as oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal, parenteral (including intramuscular, subcutaneous and intravenous), spinal (epidural, intrathecal) and central (intraventricular) administration.
[0103] A further embodiment of the present invention provides a method for isolating Vδ2-T-Exos. In certain embodiments, the method comprises the following steps:
[0104] a) providing peripheral mononuclear cells (PBMC),
[0105] b) culturing PBMCs for a first period of time in a medium in the presence of phosphoantigen and IL-2,
[0106] c) after the first period of time, culturing the PBMCs in exosome-free medium in the presence of PAM and IL-2 for a second period of time,
[0107] d) isolating exosomes from the culture supernatant after a second period of time.
[0108] In a preferred embodiment, PBMC is human PBMC. Typically, human PBMC is cultured for a period of 14 to 20 days in the presence of phosphoantigen and IL-2. After this culture period, cells are cultured for a period of 24 to 72 hours, preferably for about 48 hours, in a fresh culture medium containing no exosomes in the presence of phosphoantigen and IL-2.
[0109] Exosomes can be isolated at the end of the second culture period by various steps for isolating exosomes known in the art. Such steps may include filtration, centrifugation, ultracentrifugation, and combinations thereof.
[0110] Phosphoantigens that can be used in the method of isolating Vδ2-T-Exos include isopentenyl pyrophosphate (IPP), (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate (HMB-PP), bromohydrin pyrophosphate (BrHPP), pamidronate (PAM) or any combination thereof. Other examples of phosphoantigens that stimulate Vδ2-T cells are known in the art and such embodiments are within the scope of the present invention.
[0111] A further embodiment of the present invention provides a pharmaceutical composition comprising Vδ2-T-Exos isolated according to a method comprising the following steps:
[0112] a) providing peripheral mononuclear cells (PBMC),
[0113] b) culturing PBMCs for a first period of time in a medium in the presence of phosphoantigen and IL-2,
[0114] c) after the first period of time, culturing the PBMCs in exosome-free medium in the presence of PAM and IL-2 for a second period of time,
[0115] d) isolating exosomes from the culture supernatant after a second period of time.
[0116] The details provided above regarding the method of isolating Vδ2-T-Exos also apply to the pharmaceutical compositions of the present invention.
[0117] In addition to the Vδ2-T-Exos separated according to the methods disclosed herein, the pharmaceutical composition may also include a pharmaceutically acceptable carrier. "Pharmaceutically acceptable carrier" refers to a diluent, adjuvant or excipient, which is co-formulated with the Vδ2-T-Exos separated according to the methods disclosed herein. Generally, a "pharmaceutically acceptable carrier" is a non-toxic, biologically tolerable and biologically suitable substance for administration to a subject, such as an inert substance, which is added to a pharmacological composition or otherwise used as a diluent, adjuvant, or excipient to facilitate the administration of Vδ2-T-Exos separated according to the methods disclosed herein and compatible therewith. Examples of excipients include various sugars and starch types, cellulose derivatives, gelatin, vegetable oils and polyethylene glycol. Other examples of carriers suitable for pharmaceutical compositions are known in the art, and such embodiments are within the scope of the present invention.
[0118] The pharmaceutical compositions of the present invention can be formulated for administration to a subject by any convenient and effective route, such as oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal, parenteral (including intramuscular, subcutaneous and intravenous), spinal (epidural, intrathecal) and central (intraventricular) administration.
[0119] Other embodiments of the present invention provide a method for killing or inhibiting the growth of EBV-infected cells, comprising contacting EBV-infected cells with an effective amount of Vδ2-T-Exos isolated according to the Vδ2-T-Exos isolation method disclosed herein to kill or inhibit cell growth.
[0120] A further embodiment of the present invention also provides a method for treating EBV-induced cancer, comprising administering to a subject in need thereof a therapeutically effective amount of Vδ2-T-Exos isolated according to the Vδ2-T-Exos isolation method disclosed herein.
[0121] Some aspects of killing or inhibiting the growth of EBV-infected cells by contacting the cells with Vδ2-T-Exos are discussed above, such as the type of EBV-infected cells and the source of Vδ2-T-Exos. + These aspects are also applicable to a method of killing or inhibiting the growth of EBV-infected cells, comprising contacting the EBV-infected cells with Vδ2-T-Exos isolated according to the Vδ2-T-Exos isolation method disclosed herein.
[0122] Similarly, aspects of treating EBV-induced cancers comprising administering a therapeutically effective amount of Vδ2-T-Exos to a subject in need thereof are discussed above, such as the type of cancer, the source of Vδ2-T-Exos, and the Vδ2 + T cells, administration routes and subjects. These aspects are also applicable to methods for treating EBV-induced cancers, comprising administering to a subject in need thereof a therapeutically effective amount of Vδ2-T-Exos isolated according to the Vδ2-T-Exos isolation method disclosed herein.
[0123] Materials and methods
[0124] Study Design
[0125] The aim of this study was to determine the antitumor effects of Vδ2-T-Exos against EBV-induced B-cell lymphoma. The immune molecules with antitumor potential on Vδ2-T-Exos were characterized, and the interaction of Vδ2-T-Exos with EBV-LCL was determined. The antitumor effects of Vδ2-T-Exos against EBV-induced B-cell lymphoma in vitro were then evaluated in immunodeficient mice and humanized mice. Considering the feasibility of clinical application, the antitumor effects of autologous Vδ2-T-Exos and allogeneic Vδ2-T-Exos were compared in humanized mice. The effects of Vδ2-T-Exos on T cell responses and their potential mechanisms were further investigated. Finally, the antitumor effects of Vδ2-T-Exos in humanized mice reconstituted with whole huPBMCs, CD4-depleted huPBMCs, and CD8-depleted huPBMCs were compared. Mice were age- and sex-matched between groups. The sample size was determined by the investigator based on previous experience. The sample size and replicates are described in the figure legends. All research protocols and animal work were approved by the Institutional Review Board of the University of Hong Kong / Hospital Authority Hong Kong West Cluster and the Committee on the Use of Live Animals in Teaching and Research of the University of Hong Kong.
[0126] Isolation and characterization of Vδ2-T-Exos
[0127] PAM-amplified Vδ2-T cells were cultured in exosome-free medium for 48 hours to produce Vδ2-T-Exos. The conditioned medium was then collected and subjected to differential ultracentrifugation. Dynamic light scattering showed that the ultracentrifuged precipitate showed a bell-shaped size distribution curve representing a homogeneous population with a peak at 80 nm (Figure 1A). Electron microscopy analysis showed that the ultracentrifuged precipitate contained vesicles similar to cup-shaped exosomes (Figure 1B). Western blot analysis showed that these vesicles were positive for exosomal markers CD63, TSG101, CD81, Alix, and negative for endoplasmic reticulum protein GRP94 (Figure 1C). Density gradient ultracentrifugation of these vesicles further demonstrated that they were mainly composed of exosomes, as evidenced by the expression of exosomal markers mainly in fractions 6, 7, and 8 (Figures 8A and 8B). The expression of TCR-γδ confirmed that these vesicles were derived from Vδ2-T cells, and the lack of CD4, CD8, and CD19 expression excluded potential contamination of vesicles from other immune cells (Figure 1D). Fig. 9 ), Vδ2-T-Exos expressed considerable levels of cytolytic molecules (FasL, TRAIL), activating receptors (NKG2D), chemokine receptors (CCR5), antigen-presenting molecules (HLA-A / B / C; HLA-DR / DP / DQ), and co-stimulatory molecules (CD80, CD86) ( Figures 1E-1F ), indicating its great potential in cancer immunotherapy.
[0128] In vitro establishment of EBV-LCL
[0129] Buffy coats from EBV seropositive healthy subjects were obtained after informed consent and huPBMCs were isolated by Ficoll-Hypaque gradient centrifugation. EBV-LCLs were established as described by Xiang et al. (2014). Briefly, huPBMCs were co-incubated with EBV-containing supernatants derived from B95-8 or B95.8EBfaV-GFP cell lines and cultured in RPMI-1640 medium supplemented with 15% FBS in the presence of cyclosporin-A.
[0130] Amplification of Vδ2 and generation of Vδ2-T-Exos
[0131] Vδ2-T cells were expanded according to the protocols described by Xiang et al. (2014) and Tu et al. Briefly, huPBMCs were cultured in RPMI-1640 medium supplemented with 10% FBS and stimulated with 9 μg / ml PAM on days 0 and 3. Human recombinant interleukin 2 (IL-2; Invitrogen) was added every three days starting from day 3 at a final concentration of 200 IU / ml. After 14 to 20 days, Vδ2-T cells (purity > 95%) were transferred to 10% FBS-RPMI medium without exosomes in the presence of 9 μg / ml PAM and 500 IU / ml IL-2. Conditioned medium was collected 48 hours later and exosomes were isolated.
[0132] Isolation and characterization of Vδ2-T-Exos
[0133] Exosomes were isolated by differential ultracentrifugation at 4 °C. The conditioned medium was first centrifuged at 300 x g for 10 minutes to pellet the whole cells, 2,000 x g for 10 minutes to remove dead cells, and 10,000 x g for 30 minutes to discard cell debris. The supernatant was then filtered through a 0.22-μm syringe and then ultracentrifuged at 100,000 x g for 70 minutes (SW32Ti rotor, Beckman). The pellet was resuspended in PBS and washed again at 100,000 x g for 70 minutes. Finally, the pellet containing exosomes was dissolved in PBS. For transmission electron microscopy analysis, exosomes were fixed with 2% paraformaldehyde and placed on formvar carbon-coated copper grids. The grids were then stained with 2% phosphotungstic acid and imaged using a Philips CM100 transmission electron microscope (Philips, Eindhoven, the Netherlands). The size distribution of exosomes was determined by dynamic light scattering (DLS) analysis using a DynaPro Plate Reader (Wyatt Technology, California, USA). For Western blot analysis, proteins from cell lysates or exosomes were obtained by lysis in RIPA buffer in the presence of a protease inhibitor cocktail and separated by SDS electrophoresis on an 8-12% gel. Subsequently, the proteins were transferred to a nitrocellulose membrane and blocked with 5% skim milk. The membrane was then incubated overnight with anti-CD63, anti-CD81, anti-TSG101, anti-Alix, and anti-GRP94 antibodies (Abcam, Cambridge, UK). After incubation with the corresponding HRP-conjugated secondary antibody, the chemiluminescent signal was detected using Immobilon Classico Western HRP substrate (Millipore, MA, USA). For FACS analysis, exosomes were conjugated to 4-μm aldehyde / sulfate latex beads by overnight incubation. The exosome-bound beads were incubated with glycine to block the remaining binding sites and stained with the following fluorescently labeled antibodies and corresponding matched isotype controls: CD63, TCR-γδ, CD4, CD8, CD19, NKG2D, FasL, TRAIL, CCR5, HLA-A / B / C, HLA-DR / DP / DQ, CD80, CD86 (Biolegend, California, USA). Data acquisition was performed on a BD LSR II flow cytometer (BD Biosciences, California, USA). In addition, the pellet containing exosomes was further characterized using iodixanol gradient centrifugation as described by Lobb et al. For cell treatment, 10 μg (unless otherwise stated) of exosomes were used based on protein concentration determined by Pierce BCA protein assay kit (Pierce).In some experiments, Vδ2-T-Exos were preincubated for 30 min with the following antibodies or corresponding matched isotype controls: anti-FasL, anti-TRAIL, anti-NKG2D, anti-TCR-γδ, anti-HLA-DR / DP / DQ, anti-HLA-A / B / C, anti-CD86 (Biolegend) and washed by ultracentrifugation to remove unbound antibodies.
[0134] Interaction of Vδ2-T-Exos with recipient cells
[0135] Vδ2-T-Exos were fluorescently labeled with Dil or CFSE according to the manufacturer's instructions to monitor their interaction with recipient cells. After staining with fluorescent dyes, the exosomes were washed twice with PBS and centrifuged again at 100,000g for 70 minutes to remove excess dye. Finally, the fluorescently labeled exosomes were resuspended in PBS for further use. In some experiments, the precipitate was separated from the non-conditioned Exos-free medium using differential ultracentrifugation, and Vδ2-T-Exos were labeled as described above as a control. To determine the cellular internalization of Vδ2-T-Exos in recipient cells, Dil-labeled Exos were incubated with allogeneic EBV-LCL cells (1x10 5 ) were co-incubated. After 18 h, the incubated cells were fixed with 4% paraformaldehyde and stained with DAPI. Confocal images were acquired by LSM710 (Zeiss, Oberkochen, Germany). To evaluate the uptake efficiency of Vδ2-T-Exos, CFSE + Cells were measured using a BD LSR II flow cytometer 18 h after exposure to CFSE-labeled Exos. In some experiments, CFSE-labeled Exos were pre-incubated with neutralizing anti-TCR-γδ, anti-NKG2D antibodies or corresponding isotype controls (Biolegend) for 30 min before incubation with recipient cells. To determine whether Vδ2-T-Exos can target tumor sites in vivo, DiR-labeled Vδ2-T-Exos were injected intraperitoneally (ip) into Rag2 cells bearing EBV-induced B-cell lymphoma. - / - γc - / - The accumulation of DiR-labeled Vδ2-T-Exos in tumor tissues was detected using the IVIS Spectrum in vivo imaging system (Caliper Life Sciences, Hopkinton, USA).
[0136] Apoptosis assay
[0137] To investigate the cytolytic activity of Vδ2-T-Exos, EBV-LCL (1x10 5). Autologous normal B cells that received the same treatment were used as controls. Cell apoptosis of treated cells was measured after 18 hours using the Annexin V apoptosis detection kit (BioLegend). In some experiments, Vδ2-T-Exos were pre-incubated with neutralizing anti-FasL, anti-TRAIL antibodies or corresponding isotype controls before adding EBV-LCL. Apoptosis inhibition was calculated as the percentage of inhibition relative to the group without any treatment. In some experiments, activated caspase-3 was detected in permeabilized EBV-LCL using an anti-active caspase-3 monoclonal antibody (BD Pharmingen, California, USA) after 4 hours of exposure to Vδ2-T-Exos.
[0138] Chemotaxis assay
[0139] As described by Xiang et al., the chemotactic activity of CD3T cells was determined using a Transwell system (5.0 μm-pore size; Corning Costar). Purified CD3 T cells were treated with Vδ2-T-Exos or PBS for 48 hours and harvested. CD3 T cells pretreated with Vδ2-T-Exos were then pre-incubated for 30 minutes with neutralizing anti-CCR5 antibodies (20 mg / ml; clone 2D7, BD) or the corresponding isotype control and added to the upper chamber. CD3 T cells pretreated with PBS without any pre-incubation were used as controls. EBV-LCL-derived supernatants were harvested and added to the lower chamber after culturing in serum-free RPMI 1640 medium for 24 hours. After 4 hours, CD3 cells that migrated to the lower chamber were counted by flow cytometry using counting beads (Molecular Probes TM, USA). The migration rate of CD3 T cells in the control group was set to 100%, and the migration rates of other groups were calculated as percentages relative to the control group.
[0140] T cell proliferation and cytokine secretion assays
[0141] CD3 T cells were negatively isolated using the Pan T cell isolation kit (Miltenyi Biotec). 2x10 5CD3 T cells were treated with increasing amounts of autologous or allogeneic Vδ2-T-Exos. For proliferation assays, T cells were prestained with CFSE (Sigma-Aldrich) according to the manufacturer's instructions. After 7 days of culture, T cell proliferation was determined by flow cytometry. Cells were restimulated for 6 h with 100 ng / ml phorbol myristate (Sigma-Aldrich), 1 μg / ml ionomycin (Sigma-Aldrich), and 10 μg / ml brefeldin A (BFA, Sigma-Aldrich) before intracellular cytokine staining. Cells were collected and stained for surface markers of CD4, CD8, and intracellular staining for IFN-γ was performed. In some experiments, Vδ2-T-Exos were preincubated with neutralizing anti-HLA-A / B / C, anti-HLA-DR / DP / DQ, and anti-CD86 antibodies or corresponding isotype controls before addition to T cells. In some experiments, EBV-specific cytotoxic T lymphocytes (EBV-CTLs) were selected from EBV seropositive huPBMCs using a CD137 microbead kit (Miltenyi Biotec, USA) after stimulation with LMP2a or EBNA1 peptide pools (Miltenyi Biotec, USA) for 24 hours. The selected cells were treated with allogeneic Vδ2-T-Exos or PBS and cultured in the presence of 100 IU / ml IL-2. The culture medium was replaced every 3 days with fresh culture medium containing IL-2 and treated with Vδ2-T-Exos or PBS. Two weeks later, the cells were attacked with EBNA1 or LMP2a peptide pools for 6 hours, and BFA was added 2 hours later. EBV-CTLs were detected by flow cytometry by staining of surface markers CD4 and CD8, and intracellular staining of IFN-γ was performed. The cell number was calculated using counting beads (Molecular Probes TM , USA) were counted together.
[0142] Rag2 - / - γc - / - Establishment of EBV-induced B-cell lymphoma model in humanized and EBV-induced B-cell lymphoma mice and treatment of EBV-induced B-cell lymphoma
[0143] Rag2 - / - γc - / - Mice were raised in the Laboratory Animal Department of the University of Hong Kong. Using previously established methods, 4- to 5-week-old Rag2 mice were reconstituted with EBV seropositive whole huPBMC, CD4-depleted huPBMC, or CD8-depleted huPBMC. - / - γc - / - Mice were constructed to humanize the mice. After 4 weeks of huPBMC reconstitution, these chimeric Rag2 - / - γc - / -Stably possess a functional human peripheral immune system and are called "humanized" mice. Humanized mice or Rag2 - / - γc - / - EBV-LCL expressing EGFP or EBV-LCL (0.1x10 6 / mouse) to establish an EBV-induced B cell lymphoma model. At the specified time after inoculation of EBV-LCL, an equal volume of PBS or Vδ2-T-Exos (25 μg / mouse) was administered to the mouse peritoneum (ip) injected with EBV-LCL. For humanized mice injected with EBV-LCL, unless otherwise stated, the Vδ2-T-Exos administered were autologous relative to the reconstructed huPBMC. Disease signs (hair curling, weight loss and reduced activity), tumor incidence, tumor volume and mouse survival rate were monitored every day. Mice with subcutaneous tumor diameters greater than 17 mm were killed and counted as dead according to the regulations of the Laboratory Animal Department of the University of Hong Kong. Otherwise, mice were followed up for 100 days before being killed. Tumors and organs were retained and histological and immunohistochemical evaluations were performed.
[0144] Histological and immunohistochemical analyses
[0145] Tumor tissue was fixed with 10% formalin and embedded in paraffin for sectioning. Sections were stained with hematoxylin and eosin, in situ hybridization, immunohistochemistry, and immunofluorescence. Type 1 and type 2 small RNAs (EBER-1 / 2) encoded by EB were detected by in situ hybridization using the DIG-HRP REMBRANDT EBER ISH kit (Panpath, the Netherlands). Ki67 was detected by immunohistochemistry using anti-human Ki67 antibody (Abcam, the UK) and visualized by diaminobenzidine detection kit (Maixin, China). The infiltration of human T cells in tumor tissue was determined by immunofluorescence using anti-human CD3 antibody and imaged by LSM 710 confocal microscope (Zeiss, Germany).
[0146] Flow cytometric analysis
[0147] The cells were surface stained using the following antibodies: anti-CD63 (H5C6), anti-CD3 (HIT3a), anti-CD4 (RPA-T4), anti-CD8 (SK1), anti-CD19 (HIB19), anti-TCR-γδ (B6), anti-HLA-DQ / DP / DQ (Tü39), anti-HLA-A / B / C (W6 / 32), anti-CD80 (2D10), anti-CD86 (GL-1), anti-CD69 (FN50), anti-TRAIL (RIK-2), anti-FasL (NOK-1), anti-Fas (DX2), anti-DR5 (DJR2-4), anti-MICA / B (6D4), anti-NKG2D (1D11), and anti-CCR5 (2D7). For intracellular staining, cells were fixed, permeabilized, and then stained with anti-IFN-γ (B27) and anti-active caspase 3 (C92-605) antibodies (BD, USA) or corresponding isotype controls as described previously (18, 64). All samples were detected using a FACSLSR II flow cytometer (BD, USA) and analyzed by FlowJo software (Tree Star, USA).
[0148] Statistical analysis
[0149] Data are expressed as mean ± SEM. Differences in fluorescence intensity, apoptosis, proliferation, cytokine expression, and tumor volume were compared using paired or unpaired Student's t test. Tumor incidence and mouse survival between different groups were compared using the Kaplan-Meier log-rank test. Two-tailed tests were used for all analyses. p < 0.05 was considered significant.
[0150] All patents, patent applications, provisional applications, and publications mentioned or cited herein, including all figures and tables, are incorporated by reference in their entirety to the extent not inconsistent with the explicit teachings of this specification.
[0151] The following are examples illustrating the procedures for practicing the present invention. These examples should not be construed as limiting. Unless otherwise indicated, all percentages are by weight and all solvent mixture ratios are by volume.
[0152] Example 1 - Vδ2-T-Exos targeting EBV-induced B-cell lymphoma
[0153] To determine the interaction of Vδ2-T-Exos with tumor cells, Vδ2-T-Exos were labeled with Dil or CFSE and then added to the culture medium of EBV-transformed B lymphoblastoid cell line (EBV-LCL) for 18 h. The precipitate separated from the non-conditioned exosome-free culture medium by differential ultracentrifugation was used as a control. Confocal microscopy showed that Vδ2-T-Exos could be taken up by EBV-LCL (Figure 2A). To examine whether Vδ2-T-Exos can accumulate at tumor sites in vivo, the expression of Vδ2-T-Exos in the culture medium was detected by incubation with Rag2 as described by Xiang et al. (2014). - / - γc - / - Subcutaneous (sc) inoculation of EGFP in immunodeficient mice + EBV-LCL was used to establish EBV-induced B-cell lymphoma. DiR-labeled Vδ2-T-Exos or their control were injected intraperitoneally (ip) into EGFP-carrying + In mice with EBV-induced B-cell lymphoma. After 3 and 24 hours, the accumulation of Vδ2-T-Exos in tumor tissues was tested using an in vivo imaging system, and the results showed that Vδ2-T-Exos accumulated specifically in tumor tissues in vivo compared with controls (Figure 2B).
[0154] To further evaluate the interaction of Vδ2-T-Exos with EBV-induced B-cell lymphoma, EBV-LCL or autologous normal B cells were co-incubated with CFSE-labeled Vδ2-T-Exos or control. Flow cytometry analysis found that all EBV-LCL became CFSE-positive after treatment with CFSE-labeled Vδ2-T-Exos (Figure 2C). Importantly, the uptake efficiency of Vδ2-T-Exos by EBV-LCL was significantly higher than that of autologous normal B cells (Figure 2C), indicating that Vδ2-T-Exos can target EBV-LCL. Liposomes are nanoparticles with a nanosphere membrane-type structure that have a lipid biolayer and have similar physical properties to exosomes. Therefore, liposomes were used to treat EBV-LCL or autologous normal B cells to determine whether the different uptake efficiencies of Vδ2-T-Exos between EBV-LCL and autologous normal B cells were due to the nonspecific binding activity of nanoparticles. Interestingly, no significant difference in liposome uptake efficiency was observed between EBV-LCL and autologous normal B cells (Figure 2D), confirming that Vδ2-T-Exos targeting EBV-LCL was not due to its nonspecific binding. Importantly, the targeting effect of Vδ2-T-Exos on EBV-LCL depends on the interaction between NKG2D carried by Vδ2-T-Exos and its ligand MICA / B constitutively expressed on EBV-LCL (Figure 2D). Fig.11), because blocking NKG2D carried by Vδ2-T-Exos by anti-NKG2D neutralizing mAb significantly inhibited the targeting of Vδ2-T-Exos to EBV-LCL (Figure 2E). In contrast, blocking TCR-γδ carried by Vδ2-T-Exos could not inhibit the targeting of Vδ2-T-Exos to EBV-LCL ( Figure 2F ), indicating that the targeting of Vδ2-T-Exos to EBV-LCL is not dependent on the TCR-γδ carried by Vδ2-T-Exos. Taken together, these results indicate that Vδ2-T-Exos can target EBV-induced B-cell lymphoma.
[0155] Example 2-Vδ2-T-Exos induce apoptosis of EBV-LCL
[0156] To determine whether Vδ2-T-Exos can induce apoptosis of EBV-LCL, EBV-LCL or autologous normal B cells were treated with different concentrations of Vδ2-T-Exos for 18 hours. As shown in Figure 3A, Vδ2-T-Exos induced apoptosis of EBV-LCL in a dose-dependent manner, but it had no such effect on autologous normal B cells. This apoptosis was mainly induced by exosome fractions 6, 7 and 8 ( Figure 8C ). Vδ2-T-Exos-induced EBV-LCL apoptosis is caspase-dependent, as demonstrated by increased active caspase-3 expression in Vδ2-T-Exos-treated EBV-LCL (Figure 3B). EBV-LCL have higher levels of surface Fas and TRAIL receptor 2 (death-inducing receptor, DR5) expression levels than autologous normal B cells (Figure 3C). Vδ2-T-Exos also carry potent death-inducing ligands (FasL, TRAIL) (Figure 1E). Blocking the Fas / FasL or TRAIL / DR5 pathway using neutralizing anti-FasL or anti-TRAIL monoclonal antibodies significantly inhibited Vδ2-T-Exos-induced EBV-LCL apoptosis ( Figure 3D ), indicating that Vδ2-T-Exos-induced EBV-LCL apoptosis is at least partially mediated by the Fas / FasL and TRAIL / DR5 pathways.
[0157] Example 3 - Vδ2-T-Exos control Rag2 - / - γc - / - EBV-induced B-cell lymphoma in mice
[0158] EGFP + EBV-LCL were used to monitor the in vivo growth of EBV-induced B-cell lymphomas and were cultured in Rag2 as described by Xiang et al. (2014). - / - γc - / - Mice were subcutaneously inoculated with EGFP+ EBV-LCL further established an EBV-induced B cell lymphoma model (Figure 4A). Then, starting from day 0, Vδ2-T-Exos were intraperitoneally administered to Rag2 - / - γc - / - In mice, the maximum number of doses was 10 (Figure 4A). + After EBV-LCL, rapid development of solid tumors was detected in all PBS-treated mice by in vivo imaging (Figures 4B and 4C). These tumors were immunoblastic lymphomas and derived from human B cells, as demonstrated by positive staining for human CD20. High expression of small EBV-encoded type 1 / 2 RNA (EBER-1 / 2) indicated that these tumors were EBV-related lymphomas (Figure 4D). Vδ2-T-Exos treatment significantly reduced tumor incidence compared to the PBS-treated group (Figure 4B and 4C). Figure 4C ). Tumor growth was also significantly inhibited in Vδ2-T-Exos-treated mice, as demonstrated by in vivo imaging analysis (Figure 4B) and tumor volume (Figure 4E). Most importantly, Vδ2-T-Exos treatment significantly prolonged the survival of immunodeficient mice transplanted with EBV-induced B-cell lymphoma (Figure 4F). Histological and immunophenotypic analysis of residual tumors found that Vδ2-T-Exos-treated mice had fewer Ki-67-positive cells within EBV-induced B-cell lymphoma than PBS-treated mice, indicating that residual tumor cells in Vδ2-T-Exos-treated mice had lower proliferative capacity than those in PBS-treated mice (Figure 4D). Together, these data indicate that Vδ2-T-Exos can control Rag2 - / - γc - / - Development of EBV-induced B-cell lymphoma in mice.
[0159] To further determine whether Vδ2-T-Exos has a therapeutic effect on EBV-induced B-cell lymphoma, EGFP + EBV-LCL implanted with Rag2 - / - γc - / - Mouse ( Figure 4G ). After 14 days, mice that had developed subcutaneous tumors detected by in vivo imaging were randomly divided into two groups (Figure 4H). There was no significant difference in the fluorescence intensity of tumor cells between the two groups (Figure 4H). One group of tumor-bearing mice received Vδ2-T-Exos treatment weekly from day 14 to day 77, while the other group of tumor-bearing mice received PBS as a control ( Figure 4GPBS-treated mice had progressively growing subcutaneous tumors and all died within 56 days after EBV-LCL implantation (Figure 4I). Importantly, Vδ2-T-Exos treatment significantly limited tumor growth (Figure 4J) and improved mouse survival (Figure 4I). Histological and immunohistochemical analyses showed that these residual tumors were EBV-associated as they expressed EBER-1 / 2 ( Figure 4K In addition, there were a large number of Ki-67-positive cells in the tumor tissues of mice treated with PBS, while there were only a few Ki-67-positive cells in the tumor tissues of mice treated with Vδ2-T-Exos ( Figure 4K ). These results indicate that Vδ2-T-Exos can suppress tumor growth in immunodeficient mice bearing EBV-induced B-cell lymphoma.
[0160] Example 4 - Vδ2-T-Exos control the development of EBV-induced B-cell lymphoma in humanized mice
[0161] Humanized mice stably reconstituted with functional human peripheral blood mononuclear cells (huPBMCs) were generated as described by Xiang et al. (2014) and Tu et al. The EBV-induced B-cell lymphoma model was then established by subcutaneous inoculation of autologous EBV-LCLs in humanized mice as described by Xiang et al. (2014). After inoculation of EBV-LCLs, Vδ2-T-Exos were injected intraperitoneally into humanized mice weekly from day 0 to day 63 (Figure 5A). - / - γc - / - The situation in mice was similar, with all PBS-treated humanized mice developing subcutaneous solid tumors within 21 days of EBV-LCL inoculation (Figure 5B). During the 100-day observation period, the tumor incidence in Vδ2-T-Exos-treated humanized mice was significantly lower than that in PBS-treated humanized mice (Figure 5B). Vδ2-T-Exos treatment effectively inhibited tumor growth in humanized mice (Figure 5C). Most importantly, Vδ2-T-Exos treatment significantly prolonged the survival of humanized mice (Figure 5D). In the PBS-treated group, all humanized mice died within 56 days after EBV-LCL implantation. In contrast, during the 100-day observation period, only 3 of the 8 Vδ2-T-Exos-treated mice died, and the remaining mice remained alive (Figure 5D). Consistently, these tumors were positive for EBER1 / 2 ( Figure 5E The number of ki-67 positive cells in the residual tumor tissues of humanized mice treated with Vδ2-T-Exos was less than that of mice treated with PBS ( Figure 5E), indicating that Vδ2-T-Exos can inhibit the proliferation ability of tumor cells in vivo. These data indicate that Vδ2-T-Exos can effectively control the development of EBV-induced B-cell lymphoma in humanized mice.
[0162] Example 5 - Allogeneic Vδ2-T-Exos have better therapeutic effects than autologous Vδ2-T-Exos on EBV-induced B-cell lymphoma in humanized mice
[0163] Since most cancer patients are immunocompromised, it is difficult to expand their own Vδ2-T cells in vitro and prepare enough Vδ2-T-Exos for clinical use. Therefore, the therapeutic effects of autologous and allogeneic Vδ2-T-Exos on EBV-induced B-cell lymphoma were compared in humanized mice (Figure 5F). As shown in Figure 5G, both autologous and allogeneic Vδ2-T-Exos can control the development of EBV-induced B-cell lymphoma in humanized mice compared with the control. Importantly, allogeneic Vδ2-T-Exos are more effective than autologous Vδ2-T-Exos in controlling the development of EBV-induced B-cell lymphoma in humanized mice in terms of tumor incidence (Figure 5G), tumor growth (Figure 5H), and mouse survival (Figure 5I). In addition, the tumor cell proliferation capacity in allogeneic Vδ2-T-Exos-treated humanized mice was significantly lower than that in autologous Vδ2-T-Exos-treated mice, as demonstrated by reduced Ki-67 expression in the residual tumors of allogeneic Vδ2-T-Exos-treated mice (Figure 5J).
[0164] Immunofluorescence analysis revealed that more CD3 T cells infiltrated into tumor tissues after treatment with allogeneic Vδ2-T-Exos compared with those treated with autologous Vδ2-T-Exos or PBS ( Figure 5K ), indicating that allogeneic Vδ2-T-Exos can enhance host T cell-mediated anti-tumor responses. To confirm this, humanized mice and Rag2 - / - γc - / - The therapeutic effects of allogeneic Vδ2-T-Exos on EBV-induced B-cell lymphoma were compared between mice. Treatment with allogeneic Vδ2-T-Exos was more effective in humanized mice than in Rag2 - / - γc - / - The results showed that humanized mice and Rag2 could effectively reduce tumor incidence (Figure 5G) and tumor growth (Figure 5H) in mice and prolong mouse survival (Figure 5I). - / - γc - / -The only difference between the mice was that the humanized mice had reconstituted functional human immune cells, and these results suggested that human immune cells, especially T cells, might be involved in the antitumor activity induced by Vδ2-T-Exos in humanized mice.
[0165] Example 6 - Vδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated anti-tumor immunity.
[0166] Allogeneic Vδ2-T-Exos treatment increased the infiltration of CD3 T cells in EBV-induced B-cell lymphoma tissues in humanized mice ( Figure 5K ). It was tested whether allogeneic Vδ2-T-Exos could induce CD4 T cell- and CD8 T cell-mediated antitumor immunity against EBV-induced B cell lymphoma. Both CD4 T cells and CD8 T cells could interact with Vδ2-T-Exos, as demonstrated by the increased CFSE signals in CD4 T cells and CD8 T cells after exposure to CFSE-labeled Vδ2-T-Exos (Figures 6A and 6B). Interestingly, allogeneic Vδ2-T-Exos significantly increased the expression of CCR5 in CD4 T cells and CD8 T cells compared with the control group ( Figure 6C and 6D). In the transwell chemotaxis system, Vδ2-T-Exos treatment significantly increased the migration of T cells toward EBV-LCLs, and this migration could be significantly inhibited by anti-CCR5 blocking antibodies ( Figure 5E ). These results suggest that Vδ2-T-Exos can increase T cell infiltration into EBV-induced B-cell lymphoma tissues by upregulating CCR5 expression on T cells.
[0167] To compare the effects of autologous and allogeneic Vδ2-T-Exos on T cell responses, T cell proliferation and IFN-γ production were measured. As shown in Figures 6F-6I, both autologous and allogeneic Vδ2-T-Exos induced cell proliferation and IFN-γ production in CD4 T cells and CD8 T cells. Blocking the HLA-DR / DP / DQ or CD86 pathway with neutralizing anti-LA / DR / DP / DQ or anti-CD86 monoclonal antibodies significantly inhibited Vδ2-T-Exos-induced cell proliferation and IFN-γ production in CD4 T cells (Figures 10A, 10B, 10E, and 10F), while blocking the HLA-A / B / C or CD86 pathway with neutralizing monoclonal antibodies did not significantly affect Vδ2-T-Exos-induced cell proliferation and IFN-γ production in CD8 T cells (Figures 10C, 10D, 10G, and 10H), indicating that recognition of HLA molecules and CD86 is more important for Vδ2-T-Exos-induced CD4 cell responses than Vδ2-T-Exos-induced CD8 cell responses. Importantly, allogeneic Vδ2-T-Exos induced cell proliferation and IFN-γ production in CD4 T cells and CD8 T cells more effectively than autologous Vδ2-T-Exos (Figures 6F-6I). Therefore, allogeneic Vδ2-T-Exos induced stronger T cell responses in vitro than autologous Vδ2-T-Exos.
[0168] EBV seropositive healthy individuals carry a large number of EBV-specific T cells, which play an important role in controlling EBV-induced lymphoma. The effect of Vδ2-T-Exos on EBV-specific T cells was determined. As shown in Figures 6J-6K, allogeneic Vδ2-T-Exos significantly promoted the expansion of EBV EBNA1-specific CD4 T cells and LMP2a-specific CD8 T cell clones compared with PBS, indicating that Vδ2-T-Exos can also promote the expansion of pre-existing tumor antigen-specific T cells and enhance their therapeutic effect on EBV-induced B-cell lymphoma.
[0169] Example 7 - CD4 T cells and CD8 T cells participate in Vδ2-T-Exos-induced anti-tumor immunity in humanized mice
[0170] To further elucidate the role of CD4 T cells and CD8 T cells in allogeneic Vδ2-T-Exos-mediated anti-tumor immunity in vivo, humanized mice reconstituted with EBV seropositive whole huPBMCs, CD4-T cell-depleted huPBMCs, or CD8-T cell-depleted huPBMCs were established. After inoculation with EBV-LCLs, allogeneic Vδ2-T-Exos were intraperitoneally injected into humanized mice every week from day 0 to day 63 (Figure 7A). Compared with humanized mice reconstituted with whole huPBMCs, tumor incidence (Figure 7B), tumor volume (Figure 7C), and mouse survival ( Fig.7D ), the anti-tumor efficacy mediated by Vδ2-T-Exos was significantly reduced in humanized mice reconstructed with huPBMCs depleted of CD4-T cells or huPBMCs depleted of CD8-T cells. In addition, there was no difference in the anti-tumor efficacy mediated by Vδ2-T-Exos between humanized mice reconstructed with huPBMCs depleted of CD4-T cells and huPBMCs depleted of CD8-T cells (Figure 7). These results indicate that Vδ2-T-Exos induce CD4 T cell- and CD8 T cell-mediated anti-tumor immunity against EBV-induced B cell lymphoma in humanized mice.
[0171] Example 8 - Optimized protocol for producing more Vδ2-T-Exos with enhanced anti-tumor activity
[0172] Human peripheral blood was slowly loaded into Ficoll-Hypaque (Lymphoprep, Fresenius Kabi NorgeAS, Oslo, Norway) and centrifuged at 1,000xg for 20 minutes. After centrifugation, human peripheral blood mononuclear cells (huPBMC) were carefully separated from the interface between the plasma layer and the Ficoll-Hypaque layer. The separated PBMCs were washed twice with PBS and centrifuged at 300xg for 10 minutes to remove residual Ficoll-Hypaque. huPMBC was cultured in RPMI-1640 culture medium supplemented with 10% fetal bovine serum (FBS, Invitrogen). PAM was added on days 0 and 3 to a concentration of 9 μg / ml. Starting from day 3, recombinant human IL-2 (rhIL-2, Invitrogen) was added every 3 days to a final concentration of 200 IU / ml. After 14-20 days, the expanded Vδ2-T cells were conditioned by restimulating with 9 μg / ml PAM plus 400 IU / ml IL-2 in 10% FBS-RPMI medium without exosomes for 48 hours. After conditioning, the supernatant containing exosomes was harvested and centrifuged at 300 x g for 10 minutes to precipitate whole cells, at 2,000 x g for 10 minutes to remove dead cells, and at 10,000 x g for 30 minutes to discard cell debris. The supernatant was then filtered through a 0.22 μm syringe and then ultracentrifuged at 100,000 x g for 70 minutes. The pellet was resuspended in PBS and washed again at 100,000 x g for 70 minutes. Finally, the pellet containing exosomes was dissolved in PBS and used immediately or stored at -80 ° C. Figure 12 shows the phenotype (A), production (B) and function (CE) of exosomes from Vδ2-T cells with or without restimulation during conditioning.
[0173] It should be understood that the examples and embodiments described herein are for illustrative purposes only, and that those skilled in the art will propose various modifications or changes accordingly, which will be included in the spirit and scope of the present application and in the scope of the appended claims. In addition, any element or limitation of any invention or embodiment thereof disclosed herein may be combined with any and / or all other elements or limitations disclosed herein (alone or in any combination) or any other invention or embodiment thereof, and all such combinations are within the scope of the present invention and are not limited thereto.
[0174] References
[0175] 1.R.Kuppers,B cells under influence:transformation of B cells byEpstein-Barr virus.Nat Rev Immunol 3,801-812(2003).
[0176] 2.L.S.Young,L.F.Yap,P.G.Murray,Epstein-Barr virus:more than 50yearsold and still providing surprises.Nat Rev Cancer 16,789-802(2016).
[0177] 3.J.L.Crombie,A.S.LaCasce,Epstein Barr Virus Associated B-CellLymphomas and Iatrogenic Lymphoproliferative Disorders.Front Oncol 9,109(2019).
[0178] 4.V.R.Dharnidharka,A.C.Webster,O.M.Martinez,J.K.Preiksaitis,V.Leblond,S.Choquet,Post-transplant lymphoproliferative disorders.Nat Rev DisPrimers 2,15088(2016).
[0179] 5.R.Dolcetti,B lymphocytes and Epstein-Barr virus:the lesson of post-transplant lymphoproliferative disorders.Autoimmun Rev 7,96-101(2007).
[0180] 6.V.R.Dharnidharka,T.Mohanakumar,New approaches to treating B-cellcancers induced by Epstein-Barr virus.N Engl J Med 372,569-571(2015).
[0181] 7.JAKanakry,RFAmbinder,EBV-related lymphomas:new approaches totreatment.Curr Treat Options Oncol 14,224-236(2013).
[0182] Nat Rev Clin Oncol 9,510-519(2012) 8.CMBollard,CMRooney,HEHeslop,T-cell therapy in the treatmentof posttransplant lymphoproliferative disease.
[0183] 9.S.Beetz,D.Wesch,L.Marischen,S.Welte,HHOberg,D.Kabelitz,Innate immune functions of human gammadelta T cells.Immunobiology 213,173-182(2008).
[0184] Curr Opin Immunol 18,31-38(2006).
[0185] 11.SRCarding,PJEgan,Gammadelta T cells:functional plasticity andheterogeneity.Nat Rev Immunol 2,336-345(2002).
[0186] 12.D.Hannani,Y.Ma,T.Yamazaki,J.Dechanet-Merville,G.Kroemer,L.Zitvogel,Harnessing gammadelta T cells in anticancer immunotherapy.TrendsImmunol 33,199-206(2012).
[0187] 13.D.Kabelitz,D.Wesch,W.He,Perspectives of gammadelta T cells intumor immunology.Cancer Res 67,5-8(2007).
[0188] 14.E.J.Adams,S.Gu,A.M.Luoma,Human gamma delta T cells:Evolution andligand recognition.Cell Immunol 296,31-40(2015).
[0189] 15.H.J.Gober,M.Kistowska,L.Angman,P.Jeno,L.Mori,G.De Libero,Human Tcell receptor gammadelta cells recognize endogenous mevalonate metabolites intumor cells.J Exp Med 197,163-168(2003).
[0190] 16.M.Bonneville,E.Scotet,Human Vgamma9Vdelta2 T cells:promising newleads for immunotherapy of infections and tumors.Curr Opin Immunol 18,539-546(2006).
[0191] 17.H.Li,Z.Xiang,T.Feng,J.Li,Y.Liu,Y.Fan,Q.Lu,Z.Yin,M.Yu,C.Shen,W.Tu,Human Vgamma9Vdelta2-T cells efficiently kill influenza virus-infected lungalveolar epithelial cells.Cell Mol Immunol 10,159-164(2013).
[0192] 18.Z.Xiang,Y.Liu,J.Zheng,M.Liu,A.Lv,Y.Gao,H.Hu,K.T.Lam,G.C.Chan,Y.Yang,H.Chen,G.S.Tsao,M.Bonneville,Y.L.Lau,W.Tu,Targeted activation of humanVgamma9Vdelta2-T cells controls epstein-barr virus-induced B celllymphoproliferative disease.Cancer Cell 26,565-576(2014).
[0193] 19.Z.Xiang,W.Tu,Dual Face of Vgamma9Vdelta2-T Cells in TumorImmunology:Anti-versus Pro-Tumoral Activities.Front Immunol 8,1041(2017).
[0194] 20.H.Sicard,S.Ingoure,B.Luciani,C.Serraz,J.J.Fournie,M.Bonneville,J.Tiollier,F.Romagne,In vivo immunomanipulation of V gamma 9V delta 2 T cellswith a synthetic phosphoantigen in a preclinical nonhuman primate model.JImmunol 175,5471-5480(2005).
[0195] 21.J.M.Pitt,A.Marabelle,A.Eggermont,J.C.Soria,G.Kroemer,L.Zitvogel,Targeting the tumor microenvironment:removing obstruction to anticancerimmune responses and immunotherapy.Ann Oncol 27,1482-1492(2016).
[0196] 22.G.Raposo,W.Stoorvogel,Extracellular vesicles:exosomes,microvesicles,and friends.J Cell Biol 200,373-383(2013).
[0197] 23.B.M.Bell,I.D.Kirk,S.Hiltbrunner,S.Gabrielsson,J.J.Bultema,Designerexosomes as next-generation cancer immunotherapy.Nanomedicine 12,163-169(2016).
[0198] 24.N.L.Syn,L.Wang,E.K.Chow,C.T.Lim,B.C.Goh,Exosomes in CancerNanomedicine and Immunotherapy:Prospects and Challenges.Trends Biotechnol 35,665-676(2017).
[0199] 25.J.M.Pitt,F.Andre,S.Amigorena,J.C.Soria,A.Eggermont,G.Kroemer,L.Zitvogel,Dendritic cell-derived exosomes for cancer therapy.J Clin Invest126,1224-1232(2016).
[0200] 26.L.Lugini,S.Cecchetti,V.Huber,F.Luciani,G.Macchia,F.Spadaro,L.Paris,L.Abalsamo,M.Colone,A.Molinari,F.Podo,L.Rivoltini,C.Ramoni,S.Fais,Immune surveillance properties of human NK cell-derived exosomes.J Immunol189,2833-2842(2012).
[0201] 27.L.Zhu,S.Kalimuthu,P.Gangadaran,J.M.Oh,H.W.Lee,S.H.Baek,S.Y.Jeong,S.W.Lee,J.Lee,B.C.Ahn,Exosomes Derived From Natural Killer Cells ExertTherapeutic Effect in Melanoma.Theranostics 7,2732-2745(2017).
[0202] 28.R.J.Lobb,M.Becker,S.W.Wen,C.S.Wong,A.P.Wiegmans,A.Leimgruber,A.Moller,Optimized exosome isolation protocol for cell culture supernatantand human plasma.J Extracell Vesicles 4,27031(2015).
[0203] 29.S.E.Emam,H.Ando,A.S.A.Lila,T.Shimizu,K.Okuhira,Y.Ishima,M.A.Mahdy,F.S.Ghazy,I.Sagawa,T.Ishida,Liposome co-incubation with cancer cells secretedexosomes(extracellular vesicles)with different proteins expressions anddifferent uptake pathways.Sci Rep 8,14493(2018).
[0204] 30.W.Tu,J.Zheng,Y.Liu,S.F.Sia,M.Liu,G.Qin,I.H.Ng,Z.Xiang,K.T.Lam,J.S.Peiris,Y.L.Lau,The aminobisphosphonate pamidronate controls influenzapathogenesis by expanding a gammadelta T cell population in humanized mice.JExp Med 208,1511-1522(2011).
[0205] 31.Q.Sun,R.Burton,V.Reddy,K.G.Lucas,Safety of allogeneic Epstein-Barrvirus(EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.Br J Haematol 118,799-808(2002).
[0206] 32.C.M.Bollard,S.Gottschalk,M.Helen Huls,A.M.Leen,A.P.Gee,C.M.Rooney,Good manufacturing practice-grade cytotoxic T lymphocytes specific for latentmembrane proteins(LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.Cytotherapy 13,518-522(2011).
[0207] 33.E.Doubrovina,B.Oflaz-Sozmen,S.E.Prockop,N.A.Kernan,S.Abramson,J.Teruya-Feldstein,C.Hedvat,J.F.Chou,G.Heller,J.N.Barker,F.Boulad,H.Castro-Malaspina,D.George,A.Jakubowski,G.Koehne,E.B.Papadopoulos,A.Scaradavou,T.N.Small,R.Khalaf,J.W.Young,R.J.O'Reilly,Adoptive immunotherapy withunselected or EBV-specific T cells for biopsy-proven EBV+lymphomas afterallogeneic hematopoietic cell transplantation.Blood 119,2644-2656(2012).
[0208] 34.NNShah,K.Baird,CPDelbrook,TAFleisher,MEKohler,S.Rampertaap,K.Lemberg,CKHurley,DEKleiner,MSMerchant,S.Pittaluga,M.Sabatino,DFStroncek,ASWayne,H.Zhang,TJFry,Mack,GVHD receiving patients IL-15 / 4-1BBL activated NK cells following T-cell-depletedstem cell transplantation.Blood 125,784-792(2015).
[0209] 35.A.Tan,H.De La Pena,AMSeifalian,The application of exosomes as ananoscale cancer vaccine.Int J Nanomedicine 5,889-900(2010).
[0210] 36.B.Besse,M.Charrier,V.Lapierre,E.Dancin,O.Lantz,D.Planchard,T.LeChevalier,A.Livartoski,F.Barlesi,A.Laplanche,S .Ploix,N.Vimond,I.Peguillet,C.Thery,L.Lacroix,I.Zoernig,K.Dhodapkar,M.Dhodapkar,S.Viaud,JCSoria,KSReiners,E.Pogge von Strandmann,F.Vely,S.Rusakiewicz,A.Eggermont,JMPitt,L.Zitvogel,N.Chaput,Dendritic cell-derived exosomes as maintenanceimmunotherapy after first line chemotherapy in NSCLC.Oncoimmunology 5,e1071008(2016).
[0211] 37.B.Escudier,T.Dorval,N.Chaput,F.Andre,M.P.Caby,S.Novault,C.Flament,C.Leboulaire,C.Borg,S.Amigorena,C.Boccaccio,C.Bonnerot,O.Dhellin,M.Movassagh,S.Piperno,C.Robert,V.Serra,N.Valente,J.B.Le Pecq,A.Spatz,O.Lantz,T.Tursz,E.Angevin,L.Zitvogel,Vaccination of metastatic melanoma patients withautologous dendritic cell(DC)derived-exosomes:results of thefirst phase Iclinical trial.J Transl Med 3,10(2005).
[0212] 38.M.A.Morse,J.Garst,T.Osada,S.Khan,A.Hobeika,T.M.Clay,N.Valente,R.Shreeniwas,M.A.Sutton,A.Delcayre,D.H.Hsu,J.B.Le Pecq,H.K.Lyerly,A phase Istudy of dexosome immunotherapy in patients with advanced non-small cell lungcancer.J Transl Med 3,9(2005).
[0213] 39.J.Song,J.Huang,X.Chen,X.Teng,Z.Song,Y.Xing,M.Wang,K.Chen,Z.Wang,P.Yang,S.Hu,Donor-derived exosomes induce specific regulatory T cells tosuppress immune inflammation in the allograft heart.Sci Rep 7,20077(2016).
[0214] 40.K.V.Chow,R.M.Sutherland,Y.Zhan,A.M.Lew,Heterogeneity,functionalspecialization and differentiation of monocyte-derived dendriticcells.Immunol Cell Biol 95,244-251(2017).
[0215] 41.A.A.Alexander,A.Maniar,J.S.Cummings,A.M.Hebbeler,D.H.Schulze,B.R.Gastman,C.D.Pauza,S.E.Strome,A.I.Chapoval,Isopentenyl pyrophosphate-activated CD56+{gamma}{delta}T lymphocytes display potent antitumor activitytoward human squamous cell carcinoma.Clin Cancer Res 14,4232-4240(2008).
[0216] 42.L.Kouakanou,Y.Xu,C.Peters,J.He,Y.Wu,Z.Yin,D.Kabelitz,Vitamin Cpromotes the proliferation and effector functions of human gammadelta Tcells.Cell Mol Immunol,(2019).
[0217] 43.G.Qin,H.Mao,J.Zheng,S.F.Sia,Y.Liu,P.L.Chan,K.T.Lam,J.S.Peiris,Y.L.Lau,W.Tu,Phosphoantigen-expanded human gammadelta T cells display potentcytotoxicity against monocyte-derived macrophages infected with human andavian influenza viruses.J Infect Dis 200,858-865(2009).
[0218] 44.M.W.Khan,S.M.Curbishley,H.C.Chen,A.D.Thomas,H.Pircher,D.Mavilio,N.M.Steven,M.Eberl,B.Moser,Expanded Human Blood-Derived gammadeltaT CellsDisplay Potent Antigen-Presentation Functions.Front Immunol 5,344(2014).
[0219] 45.M.Brandes,K.Willimann,B.Moser,Professional antigen-presentationfunction by human gammadelta T Cells.Science 309,264-268(2005).
[0220] 46.M.S.Braza,B.Klein,Anti-tumour immunotherapy with Vgamma9Vdelta2 Tlymphocytes:from the bench to the bedside.Br J Haematol 160,123-132(2013).
[0221] 47.A.Y.Jong,C.H.Wu,J.Li,J.Sun,M.Fabbri,A.S.Wayne,R.C.Seeger,Large-scale isolation and cytotoxicity of extracellular vesicles derived fromactivated human natural killer cells.J Extracell Vesicles 6,1294368(2017).
[0222] 48.L.Zitvogel,A.Regnault,A.Lozier,J.Wolfers,C.Flament,D.Tenza,P.Ricciardi-Castagnoli,G.Raposo,S.Amigorena,Eradication of established murine tumors using a novel cell-free vaccine:dendritic cell-derived exosomes.NatMed 4,594-600(1998).
[0223] 49. Z. Lu, B. Zuo, R. Jing,
[0224] 50.I.Parolini,C.Federici,C.Raggi,L.Lugini,S.Palleschi,A.De Milito,C.Coscia,E.Iessi,M.Logozzi,A.Molinari,M.Colone,M.Tatti,M.Sargiacomo,S.Fais,Microenvironmental pH is a key factor for exosome trafficking in tumor cells.JBiol Chem 284,34211-34222(2009).
[0225] 51.JWFabre,The allogeneic response and tumor immunity.Nat Med 7,649-652(2001).
[0226] 52.N.W.Nisbet,M.Simonsen,M.Zaleski,The frequency of antigen-sensitivecells in tissue transplantation.A commentary on clonal selection.J Exp Med129,459-467(1969).
[0227] 53.H.A.Gjertsen,K.E.Lundin,T.Hansen,E.Thorsby,T cells specific forviral antigens presented by HLA-Dw4 recognize DR13 on allogeneic cells:apossible mechanism for induction of rejection.Transplantation proceedings 25,70-71(1993).
[0228] 54.S.R.Burrows,R.Khanna,J.M.Burrows,D.J.Moss,An alloresponse inhumans is dominated by cytotoxic T lymphocytes(CTL)cross-reactive with asingle Epstein-Barr virus CTL epitope:implications for graft-versus-hostdisease.J Exp Med 179,1155-1161(1994).
[0229] 55.S.Y.Li,Y.Liu,C.F.Xu,S.Shen,R.Sun,X.J.Du,J.X.Xia,Y.H.Zhu,J.Wang,Restoring anti-tumor functions of T cells via nanoparticle-mediated immunecheckpoint modulation.J Control Release 231,17-28(2016).
[0230] 56.D.A.Newton,P.M.Acierno,F.J.Brescia,E.A.Brown,S.Gattoni-Celli,Semi-allogeneic vaccines for patients with cancer and AIDS.J Immunother 25,334-341(2002).
[0231] 57.L.D.Barber,J.A.Madrigal,Exploiting beneficial alloreactive Tcells.Vox Sang 91,20-27(2006).
[0232] 58.T.D.de Gruijl,A.J.van den Eertwegh,H.M.Pinedo,R.J.Scheper,Whole-cell cancer vaccination:from autologous to allogeneic tumor-and dendriticcell-based vaccines.Cancer Immunol Immunother 57,1569-1577(2008).
[0233] 59.G.Qin,Y.Liu,J.Zheng,I.H.Ng,Z.Xiang,K.T.Lam,H.Mao,H.Li,J.S.Peiris,Y.L.Lau,W.Tu,Type 1 responses of human Vgamma9Vdelta2 T cells to influenza Aviruses.J Virol 85,10109-10116(2011).
[0234] 60.G.Qin,Y.Liu,J.Zheng,Z.Xiang,I.H.Ng,J.S.Malik Peiris,Y.L.Lau,W.Tu,Phenotypic and functional characterization of human gammadelta T-cell subsetsin response to influenza A viruses.J Infect Dis 205,1646-1653(2012).
[0235] 61.M.Alnaggar,Y.Xu,J.Li,J.He,J.Chen,M.Li,Q.Wu,L.Lin,Y.Liang,X.Wang,J.Li,Y.Hu,Y.Chen,K.Xu,Y.Wu,Z.Yin,Allogenic Vgamma9Vdelta2 T cell as newpotential immunotherapy drug for solid tumor:a case study forcholangiocarcinoma.J Immunother Cancer 7,36(2019).
[0236] 62.P.Speck,R.Longnecker,Epstein-Barr virus(EBV)infection visualizedby EGFP expression demonstrates dependence on known mediators of EBVentry.Arch Virol 144,1123-1137(1999).
[0237] 63.C.Thery,S.Amigorena,G.Raposo,A.Clayton,Isolation andcharacterization of exosomes from cell culture supernatants and biologicalfluids.Curr Protoc Cell Biol Chapter 3,Unit 3 22(2006).
[0238] 64.K.Ni,M.Liu,J.Zheng,L.Wen,Q.Chen,Z.Xiang,K.T.Lam,Y.Liu,G.C.Chan,Y.L.Lau,W.Tu,PD-1 / PD-L1 Pathway Mediates the Alleviation of PulmonaryFibrosis by Human Mesenchymal Stem Cells in Humanized Mice.Am J Respir CellMol Biol 58,684-695(2018).
Claims
1. Preparation of Vδ2 + The method for producing T cell exosomes (Vδ2-T-Exos) comprises the following steps: a) providing peripheral mononuclear cells (PBMC), b) culturing the PBMCs in a culture medium in the presence of a phosphoantigen and IL-2 for a first period of time, wherein the first period of time is 14 to 20 days, c) after the first period of time, culturing the PBMCs in an exosome-free medium in the presence of phosphoantigen and IL-2 for a second period of time, wherein the second period of time is 24 to 72 hours, d) isolating exosomes from the culture supernatant after said second period of time.
2. The method of claim 1, wherein the PBMCs are human PBMCs.
3. The method of claim 1 or 2, wherein the separation step comprises one or more of the following: filtration, centrifugation.
4. The method of claim 3, wherein the centrifugation is further ultracentrifugation.
5. The method of any one of claims 1 to 4, wherein the phosphoantigen is isopentenyl pyrophosphate (IPP), (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate (HMB-PP), bromohydrin pyrophosphate (BrHPP), pamidronate (PAM), or any combination thereof.
6. Vδ2 prepared according to the method of claim 1 + Use of T cell exosomes in the preparation of a medicament for killing or inhibiting the growth of EBV-infected cells.
7. The use according to claim 6, wherein the EBV-infected cells are EBV-infected lymphocytes or EBV-infected epithelial cells.
8. The use according to claim 7, wherein the EBV-infected lymphocytes are EBV-infected B lymphocytes.
9. The use according to claim 8, wherein the EBV-infected lymphocytes are EBV-infected neoplastic B lymphocytes.
10. The use of claim 7, wherein the EBV-infected epithelial cells are EBV-infected neoplastic epithelial cells.
11. The method according to any one of claims 6 to 10, wherein the exosomes are isolated from Vδ2 cells that are autologous to the EBV-infected cells. + T cells.
12. The method according to any one of claims 6 to 10, wherein the exosomes are isolated from Vδ2 cells allogeneic to the EBV infected cells. + T cells.
13. Vδ2 prepared according to the method of claim 1 + Use of T cell exosomes in the preparation of a medicament for treating EBV-induced cancer.
14. The use according to claim 13, wherein the cancer is of lymphocytic origin or of epithelial origin.
15. The use according to claim 14, wherein the EBV-induced cancer of lymphocytic origin is EBV-induced: Burkitt's lymphoma, Hodgkin's lymphoma, diffuse large B-cell lymphoma or lymphoproliferative disease.
16. The use of claim 14, wherein the EBV-induced cancer of epithelial origin is EBV-induced nasopharyngeal carcinoma (NPC) or EBV-induced gastric cancer.
17. The method according to any one of claims 13 to 16, wherein the exosomes are obtained from Vδ2 of the subject. + T cells.
18. The use according to any one of claims 13 to 17, wherein the exosomes are obtained from Vδ2 of the subject when it is known that the subject does not have cancer. + T cells.
19. The use according to any one of claims 13 to 16, wherein the exosomes are obtained from Vδ2 of an individual allogeneic to the subject. + T cells.
20. The use of any one of claims 13 to 19, wherein the exosomes are administered by a route selected from oral, rectal, nasal, buccal, sublingual, vaginal, intramuscular, subcutaneous, intravenous, epidural, intrathecal and central.
21. A composition comprising Vδ2 prepared according to the method of claim 1 + T cell exosomes and a pharmaceutically acceptable carrier.
22. The composition of claim 21 formulated for administration to a subject by a route selected from the group consisting of oral, rectal, nasal, buccal, sublingual, vaginal, intramuscular, subcutaneous, intravenous, epidural, intrathecal, and central.
